Molecular pathogenesis of spinal and bulbar muscular atrophy

被引:15
|
作者
Merry, DE [1 ]
机构
[1] Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA
关键词
androgen receptor; polyglutamine; Kennedy's disease; protein aggregation;
D O I
10.1016/S0361-9230(01)00594-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Studies of the molecular pathogenesis of spinal and bulbar muscular atrophy, as well as of the other polyglutamine repeat diseases, has led to an understanding of the role of protein accumulation in disease pathogenesis. Aggregation of the expanded repeat androgen receptor (AR), rather than playing a pathogenic role, likely reflects the insoluble nature of the misfolded AR. Proteolytic processing of the expanded AR at various stages of its metabolism may contribute to cellular toxicity through the enhancement of AR insolubility, and potentially through the disruption of normal proteolytic degradation processes. The finding that molecular chaperones not only promote solubility, but also enhance the degradation of expanded polyglutamines as well, make them promising targets for therapeutic development. Understanding the role of ligand binding in expanded AR metabolism may provide additional avenues of therapeutic manipulation as well. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 50 条
  • [31] Mitochondrial abnormalities in spinal and bulbar muscular atrophy
    Ranganathan, Srikanth
    Harmison, George G.
    Meyertholen, Kristin
    Pennuto, Maria
    Burnett, Barrington G.
    Fischbeck, Kenneth H.
    HUMAN MOLECULAR GENETICS, 2009, 18 (01) : 27 - 42
  • [32] Developing treatment for spinal and bulbar muscular atrophy
    Fischbeck, Kenneth H.
    PROGRESS IN NEUROBIOLOGY, 2012, 99 (03) : 257 - 261
  • [33] Clinical features of spinal and bulbar muscular atrophy
    Rhodes, Lindsay E.
    Freeman, Brandi K.
    Auh, Sungyoung
    Kokkinis, Angela D.
    La Pean, Alison
    Chen, Cheunju
    Lehky, Tanya J.
    Shrader, Joseph A.
    Levy, Ellen W.
    Harris-Love, Michael
    Di Prospero, Nicholas A.
    Fischbeck, Kenneth H.
    BRAIN, 2009, 132 : 3242 - 3251
  • [34] Pathogenesis of Spinal Muscular Atrophy
    Claus, P.
    KLINISCHE NEUROPHYSIOLOGIE, 2012, 43 (03) : 203 - 205
  • [35] Molecular Pathophysiology and Disease-Modifying Therapies for Spinal and Bulbar Muscular Atrophy
    Katsuno, Masahisa
    Banno, Haruhiko
    Suzuki, Keisuke
    Adachi, Hiroaki
    Tanaka, Fumiaki
    Sobue, Gen
    ARCHIVES OF NEUROLOGY, 2012, 69 (04) : 436 - 440
  • [36] Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
    Lopez-Cortes, Andres
    Echeverria-Garces, Gabriela
    Ramos-Medina, Maria Jose
    BIOLOGY-BASEL, 2022, 11 (06):
  • [37] Troponin T in spinal and bulbar muscular atrophy (SBMA)
    Musso, Giulia
    Blasi, Lorenzo
    Mion, Monica Maria
    Fortuna, Andrea
    Sabbatini, Daniele
    Zaninotto, Martina
    Bello, Luca
    Pegoraro, Elena
    Basso, Daniela
    Plebani, Mario
    Soraru, Gianni
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 456
  • [38] Treatment of spinal and bulbar muscular atrophy with leuprorelin acetate
    Yamamoto, Tomotaka
    Ohtsu, Hiroshi
    Tsuji, Shoji
    ANNALS OF NEUROLOGY, 2007, 62 : S68 - S68
  • [39] A Quality of Life Measurement for Spinal and Bulbar Muscular Atrophy
    Guber, Robert
    Kokkinis, Angela
    Schindler, Alice
    Bendixen, Roxanna
    Heatwole, Chad
    Fischbeck, Kenneth
    Grunseich, Christopher
    NEUROLOGY, 2017, 88
  • [40] Current Status of Treatment of Spinal and Bulbar Muscular Atrophy
    Tanaka, Fumiaki
    Katsuno, Masahisa
    Banno, Haruhiko
    Suzuki, Keisuke
    Adachi, Hiroaki
    Sobue, Gen
    NEURAL PLASTICITY, 2012, 2012